RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish Observational Cohort Study
- PMID: 37216905
- PMCID: PMC10407693
- DOI: 10.1093/jnci/djad089
RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish Observational Cohort Study
Conflict of interest statement
There are no conflicts of interest to declare.
Comment in
-
Response to Van Cauwenberge, Borremans, Van Houdt, et al.J Natl Cancer Inst. 2023 Aug 8;115(8):1000. doi: 10.1093/jnci/djad088. J Natl Cancer Inst. 2023. PMID: 37216920 Free PMC article. No abstract available.
Comment on
-
Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.J Natl Cancer Inst. 2022 Oct 6;114(10):1347-1354. doi: 10.1093/jnci/djac112. J Natl Cancer Inst. 2022. PMID: 35854422 Free PMC article.
References
-
- Shulman LP, Portman DJ, Lee WC, et al. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice. J Womens Health (Larchmt). 2008;17(4):569-578. - PubMed
-
- Pintilie M. Competing Risks: A Practical Perspective. Wiley; 2006;1-224. doi: 10.1002/9780470870709. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
